# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price ...
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price ...
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target fro...
Stifel analyst Rick Wise maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $9 to $6.
Treace Medical Concepts (NASDAQ:TMCI) affirms FY2025 sales outlook from $224.000 million-$230.000 million to $224.000 million-$...
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate ...
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a...